Skip to main content
OpenTrials
Completed

NCT Number: NCT00178620

Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates.

Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Memorial Hermann Hospital / The University of Texas HSC

Houston, Texas, 77030, United States

About this study

To demonstrate feasibility of the project in a pilot trial we plan to enroll up to 500 patients to pre-hospital thrombolysis/clot busting followed by emergent catheterization and stenting of the problematic or culprit artery.

This will comprise an EMS system capable of performing pre-hospital ECGs followed by emergent transportation to a Level I Cardiovascular Center where the patients will be taken to urgent cardiac catheterization and emergent stenting of the culprit artery.

Patients identified as having typical symptoms of acute MI and an ECG consistent with acute ST elevation MI will be screened in the field by paramedics or in the spoke hospitals by the ED attending physicians using the screening form. Verbal Consent will be obtained for receiving acute therapy for their MI as outlined in the protocol. After therapy is initiated in the field or at the spoke hospital, the patients will be transported as quickly as possible to the receiving Level I Cardiovascular Center (Hub Hospital). The ED personnel in the Level I Cardiovascular Center will have activated the Interventional Cardiovascular Team and the Cath Lab personnel after having received the initial qualifying transmitted ECG.

Once the patient arrives, informed consent will be obtained by the ED investigator and/or in-house Cardiology fellow for enrollment in the PATCAR Trial. Thrombolytic ineligible patients will also be collect for this study and also go directly to the Cath Lab for PCI. Study coordinators will enter the data into the Case Report Forms and forward the completed forms to Westat-ALA for data capture in the database. In addition to the qualifying ECG, ECG's will be obtained at hospital discharge/transfer. All patients will follow the current standard of care for STEMI/heart attacks patients. Patients will have a Cardiac MRI done on day 3 or 5 of their hospital stay, to measure the size and amount of damage the heart suffered as a result of their Heart attack.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ischemic discomfort (squeezing, crushing, or pressure, sub-sternal, unrelated to breathing or movement), epigastric discomfort or pre-syncopal symptoms with diaphoresis, lasting > 30 minutes.
  • ST elevation > 0.1 mV in 2 or more contiguous limb leads or > 0.2 mV in 2 or more contiguous pre-cordial leads.
  • Less than 6 hours after onset of sustained chest pain.
  • Age 18 years or older.

Exclusion criteria

  • Chest pain described as ripping or tearing, radiating to the back and/or down the leg, and/or systolic blood pressure > 15 mmHg difference in each arm.
  • Suspected cocaine or amphetamine use within previous 3 days.
  • Known or suspected pregnancy.
  • Cardiac arrest requiring intubation.
  • Cardiac arrest requiring greater than 20 minutes CPR.
  • Coronary intervention (PTCA/stent/CABG) within previous 4 weeks.

Treatment and study plan

Reteplase 10 Units (U) plus a second dose of reteplase 10 U

Drug

Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose

Other names: Retavase

Reteplase 10 U

Drug

Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose

Other names: Retavase

Urgent Percutaneous Coronary Intervention (PCI)

Procedure

Primary Percutaneous Coronary Intervention (PCI)

Procedure

Primary outcomes

  1. Mortality at 30 Days

    Time frame: 30 day

Secondary outcomes

  1. Infarction Size as Measured by Cardiac Magnetic Resonance Imaging (MRI)

    Time frame: 1 year

  2. Reduction in Time From Onset of Pain to Reperfusion

    Time frame: 1 year

  3. Angiographic Documentation of Reperfusion

    Time frame: 1 year

  4. Electrocardiogram (ECG) ST Segment Elevation Recovery

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center, Houston

Other

Registry information

Official study title

PATCAR Pilot Trial: A Phase 4 Study, Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

Acronym: PATCAR

Important dates

Study start
2003
Primary completion
2009
Study completion
2009
First posted
Sep 15, 2005
Registry last updated
Sep 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.